• Dupixent and vaccines bring Sanofi back to growth fiercepharma
    November 28, 2018
    With competition to its diabetes and cardiovascular franchises hurting Sanofi, CEO Olivier Brandicourt pledged a return to growth starting from the second half of 2018. And thanks mainly to Dupixent and now-recovered vaccines sales, he kept his word.
PharmaSources Customer Service